Lozewicz S, Robertson C F, Costello J F, Price J F
Clin Allergy. 1984 Mar;14(2):187-91. doi: 10.1111/j.1365-2222.1984.tb02651.x.
Sodium cromoglycate (SCG) has recently been formulated as a pressurized aerosol. Twenty-five asthmatic outpatients taking SCG via the Spinhaler were studied in a double-dummy, double-blind cross-over trial in which subjects took Spincaps containing 20 mg of SCG for 2 months, and for the alternate 2 months were treated with SCG aerosol delivering 1 mg/actuation. There was no evidence of clinical deterioration occurring during the period on aerosol SCG. During this period however cough frequency was significantly lower and when data for the 8-13 and 14-46 year age groups were analysed separately, this decrease was seen to be confined to the younger group. Furthermore, this group but not the adults, showed a significant improvement in morning peak expiratory flow rate. We conclude that the aerosol preparation of SCG is a useful alternative to delivery by Spinhaler for patients who are able to coordinate, and that it may have special advantages for children.
色甘酸钠（SCG）最近已被制成一种加压气雾剂。在一项双盲、双模拟交叉试验中，对25名通过Spinhaler吸入器使用SCG的哮喘门诊患者进行了研究。在该试验中，受试者服用含20毫克SCG的Spincaps胶囊2个月，在接下来的2个月改用每次喷送1毫克SCG的气雾剂进行治疗。没有证据表明在使用气雾剂SCG期间临床症状出现恶化。然而在此期间咳嗽频率显著降低，当分别分析8 - 13岁和14 - 46岁年龄组的数据时，发现这种降低仅局限于较年轻的组。此外，仅该较年轻组而非成年人，晨峰呼气流量速率有显著改善。我们得出结论，对于能够配合的患者，SCG气雾剂制剂是一种可替代Spinhaler吸入器给药的有用方式，并且它可能对儿童具有特殊优势。
